Xenon Pharmaceuticals Inc. (XENE)
NASDAQ: XENE · Real-Time Price · USD
62.76
+20.82 (49.64%)
At close: Mar 9, 2026, 4:00 PM EDT
62.62
-0.14 (-0.22%)
Pre-market: Mar 10, 2026, 7:00 AM EDT
Xenon Pharmaceuticals Employees
As of December 31, 2025, Xenon Pharmaceuticals had 370 total employees, including 358 full-time and 12 part-time employees. The number of employees increased by 43 or 13.15% compared to the previous year.
Employees
370
Change (1Y)
43
Growth (1Y)
13.15%
Revenue / Employee
$20,270
Profits / Employee
-$934,892
Market Cap
5.22B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 370 | 43 | 13.15% | 358 | 12 |
| Dec 31, 2024 | 327 | 68 | 26.25% | 316 | 11 |
| Dec 31, 2023 | 259 | 46 | 21.60% | 251 | 8 |
| Dec 31, 2022 | 213 | 60 | 39.22% | 203 | 10 |
| Dec 31, 2021 | 153 | 24 | 18.60% | 149 | 4 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Caris Life Sciences | 1,769 |
| PTC Therapeutics | 991 |
| CRISPR Therapeutics AG | 393 |
| Mirum Pharmaceuticals | 372 |
| Immunovant | 362 |
| Apogee Therapeutics | 261 |
| CG Oncology | 142 |
| Scholar Rock Holding | 128 |
XENE News
- 15 hours ago - Xenon Pharmaceuticals Announces Proposed Public Offering - GlobeNewsWire
- 16 hours ago - Crude Oil Rises Around 4%; Xenon Pharmaceuticals Shares Surge - Benzinga
- 16 hours ago - Xenon Pharmaceuticals Inc. (XENE) Discusses Positive Top Line Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures Transcript - Seeking Alpha
- 19 hours ago - Xenon: Shares Soar On Seizure Data, But Valuation May Be Overcooked - Seeking Alpha
- 21 hours ago - Xenon Pharmaceuticals Rallies After Pivotal Data Shows Major Drop In Monthly Seizures - Benzinga
- 23 hours ago - Xenon Pharma's epilepsy drug meets main goal in late-stage trial - Reuters
- 1 day ago - Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS) - GlobeNewsWire
- 1 day ago - Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026 - GlobeNewsWire